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Daniel F HayesAbstract
The era of Personalized Medicine implies getting the right treatment to the right patient at the right schedule and dose
at the right time. Tumor biomarker tests are keys to accomplishing this goal successfully. However, much of the
translational research regarding tumor biomarker tests has been haphazard, often using data and specimen sets of
convenience and ignoring many of the principles of the scientific method. In papers published simultaneously in
BMC Medicine and Nature, McShane and colleagues have proposed a checklist of criteria that should be followed by
investigators planning to conduct prospective clinical trials directed towards generating high levels of evidence to
demonstrate whether a tumor biomarker test has clinical utility for a specific context. These criteria were generated in
response to a roadmap reported by a committee convened by the U.S. Institute of Medicine for generation of
omics-based biomarker tests. Taken together with several other initiatives to increase the rigor of tumor biomarker
research, these criteria will increase the perception of value for tumor biomarker test research and application in the clinic.
Please see related article: http://www.biomedcentral.com/1741-7015/11/220.
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Over the last few years, one cannot open a clinical journal
without an article ostensibly addressing some component
of ‘Personalized’ or ‘Individualized’ or ‘Precision’ medicine.
This trend is particularly evident in the field of oncology.
Personalized oncology is simply defined as ‘getting the right
treatment to the right patient at the right dose and schedule
at the right time [1].’ These papers usually report some
component of the use of tumor biomarkers to better select
which patients might be more likely to benefit from a given
clinical care strategy, by virtue of either being more likely to
respond or less likely to suffer toxicities.
The use of diagnostics to better treat patients is as old
as medicine itself. Within the field of oncology, pathologic
findings have been used to direct various chemotherapy
regimens based on tissue of origin. More precisely, estro-
gen receptor (ER) has served as a predictive biomarker in
breast cancer for selection of endocrine therapy since the
mid-1970s [2,3]. In the last 15 years HER2 has joined ERCorrespondence: hayesdf@umich.edu
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2013in breast cancer as a predictive factor, in this case serving
as a marker for therapies directed towards the HER2
protein [4,5]. More recently, other examples of useful bio-
markers to direct novel targeted treatments in colorectal,
lung, and hematologic malignancies have been reported.
Perhaps the most compelling stimulus for the interest
in personalized medicine has grown from the omics-
revolution of the last 15 years [6]. Based on the cloning
of the human genome in the latter part of the 1990s,
fascinating technologies that allow the simultaneous
measurement of thousands of analytes (RNA, proteins,
metabolites and so on) have been coupled with sophisti-
cated bioinformatics to permit development of multi-
parameter signatures that correlate with either biological
or clinical phenotypes and outcomes.
Sadly, in spite of these amazing advances, only a few
diagnostics have been adopted successfully into routine
clinical care of patients with cancer [7]. Many reasons
for the disappointing output of clinically useful tumor
biomarkers have been addressed over the last decade
[6,8-12]. This commentary summarizes the reasons for
the low output of clinically useful tumor biomarkers and
also discusses the ways in which this is being addressed.is is an Open Access article distributed under the terms of the Creative
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In order that tumor biomarkers have clinical impact,
there are two issues that must be addressed. First, it is
important to distinguish a tumor biomarker from a tumor
biomarker test. The term ‘biomarker’ usually refers to a bio-
logical factor or process that is identified in malignant but
not normal tissues or other biospecimens. In contrast, a
tumor biomarker test is a specific assay for the biomarker.
Indeed, it is possible that many tests may be developed for
one tumor biomarker. HER2 offers an ideal example. HER2
can be over-expressed at the message and/or protein level,
which can be a result of either amplification or regulatory
control [4,5]. Furthermore, activating HER2 mutations have
recently been reported in breast cancers that have normal
copy gene numbers [13]. Circulating extra-cellular domain
of the HER2 protein levels may be detected in serum [7].
There are many tests that have been generated to identify
and quantify these different circumstances, each with vari-
able use in the clinic. Regardless, it is essential that any
tumor biomarker that is to be used to direct care is accur-
ate, reproducible, and reliable – put simply, it must have
analytical validity [10].
Second, a tumor biomarker test must have clinical
utility – a term coined by the Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Initiative
in 2009 [10]. Clinical utility does not just imply that
the tumor biomarker test divides a population into two
separate groups with statistical significance (a circumstance
EGAPP termed ‘clinical validity’). Rather, clinical utility is
achieved if high levels of evidence have been generated
that consistently demonstrate that applying the tumor bio-
marker test results in improved outcomes for the patient
when compared to not using the assay to direct care. High
levels of evidence may come either from prospectively
directed clinical trials [14,15] or from ‘prospective retro-
spective’ studies using archived specimens derived from
previously conducted clinical trials [11].
Although these concepts apply to any diagnostic in
general, and to any tumor biomarker specifically, the
advent of omics-based tumor biomarker studies has led
to a plethora of reports of putative assays that are highly
confounded by the astounding number of data points
applied to a vanishingly small patient dataset. Recently,
in a highly publicized situation, an unstable set of signatures
that had no evidence of analytical stability was used to dir-
ect specific therapies within prospective clinical trials. This
unfortunate set of circumstances led to a comprehensive
review by a committee of experts, convened by the United
States Institute of Medicine (IOM), of the translation of
omics-based tests to clinical trials, and ultimately to clinical
care [6]. The IOM committee generated a roadmap for
investigators to follow during development of a putative
new omics-based tumor biomarker test. This roadmap
leads investigators through three separate but linkedstages of development: Discovery, Test Development,
and Evaluation of Clinical Utility and Use (Figure 1).
A roadmap for the improvement of tumor biomarker
research
In a correspondence article in BMC Medicine [16], and
in an accompanying companion paper published simul-
taneously in Nature [17], McShane and her colleagues
extend these efforts to improve tumor biomarker research
by providing a checklist of criteria for the use of omics-
based predictors in clinical trials. This checklist grew out
of a workshop convened by the United States National
Cancer Institute (NCI), specifically to consider the recom-
mendations from the IOM committee. The criteria pertain
to all three stages of the IOM roadmap (Figure 1), but
they are especially pertinent to investigators who have
elected to cross the ‘Bright Line’ illustrated in Figure 1
that distinguishes the Discovery and Test Validation
Stage from the Evaluation of Clinical Utility and Use
Stage. The criteria are particularly directed towards those
investigators who have chosen the strategy of conducting
a prospective clinical trial to ‘test the test’ (see Figure 1,
middle and far right side of bottom panel). Of note, many
of these criteria are not novel – indeed, McShane has
worked tirelessly with many colleagues calling for trans-
parent reporting of pre-analytical (the ‘BRISQ criteria’)
and study design and analytical (the ‘REMARK criteria’)
issues in papers describing tumor biomarker results
[8,9,12]. However, the current publication is a compre-
hensive, yet concise, set of criteria about which any in-
vestigator considering a clinical trial to generate high
levels of evidence for clinical utility of a tumor biomarker
test must be aware.
Why is this checklist needed? Because, ‘A Bad Tumor
Marker Is as Bad as a Bad Drug [18].’ Ironically, over the
last century, the scientific community has developed very
strict criteria for scientific discovery and reporting of
both basic laboratory research and clinical trial investi-
gations. For example, basic laboratory researchers fol-
low a strict code of scientific methods ensuring proper
experimental design, using appropriate control condi-
tions and insisting on reproducibility. Likewise, clinical
therapeutic trialists use prospectively written protocols
that describe the objectives and subject eligibility for
the trial and stipulate how the therapeutic agent will be
prepared and administered. Moreover, the protocol states
in great detail what endpoints will be evaluated and how
they will be measured (with specific scales and criteria)
and, finally, provides a specific statistical plan that must
be followed during and at the conclusion of the trial.
These features are designed to minimize unintentional,
or intentional, biases and reporting, in an effort to pro-
duce believable, reproducible results – the hallmark of
the scientific method.
Figure 1 Institute of Medicine Roadmap for omics-based tumor biomarker test development. The first stage encompasses discovery of a
biologically, and perhaps clinically, interesting omics-based tumor biomarker and development of an analytically-validated tumor biomarker test
with clinical validity. The second stage is directed towards evaluation for clinical utility and use of the tumor biomarker test, either in a
prospective-retrospective study using archived specimens or in prospective clinical trials designed to ‘test the test’ for its intended clinical use.
Reprinted with permission from reference [6] by the National Academy of Sciences, Courtesy of the National Academies Press, Washington, D.C.
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putative biomarkers from basic research to clinical stud-
ies have often ignored some of these fundamental princi-
ples of the scientific process. Rather, tumor biomarker
investigations have, too often, been studies of conveni-
ence, in which the investigators have applied an assay
(which may or may not have analytical validity) to some
available patient specimens, observed separation in some
outcome of the population at hand with a P value <0.05,
and declared victory. Although such a study may suggest
clinical validity, the results rarely, if ever, demonstrateclinical utility. Unfortunately, very few investigators take
the next step across the Bright Line into the Evaluation
for Clinical Utility and Use Stage outlined in the IOM
roadmap (Figure 1). Consequently, while thousands of
manuscripts have been published in the peer-reviewed
literature, few tumor biomarker tests have sufficiently
high levels of evidence of clinical utility to warrant rec-
ommendations for use to direct patient care. The NCI
Workshop criteria proposed by McShane et al, which are
carefully explained in the BMC Medicine Explanation and
Elaboration article [16], represent a further effort to provide
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IOM Committee.
Conclusions
Clearly, the scientific, regulatory, reimbursement, medical
and lay communities do not value tumor biomarker tests to
the same extent as cancer therapeutics. Recently, many of
these concepts have been distilled into what has been desig-
nated a ‘vicious cycle’ that emerges from the devaluation of
tumor biomarker research and clinical application. Several
transformative recommendations were suggested to break
the cycle and create a ‘virtuous cycle [19].’ If we do not
approach this problem systematically, as suggested by the
IOM and the NCI Working Committee, the promise of
personalized oncology will never materialize. Worse, assays
of questionable value will be marketed to the public, caveat
emptor, possibly resulting in unknown amounts of over-
and under-treatment. It is essential that investigators con-
sidering generation of studies to develop Level 1 evidence
supporting clinical utility of tumor biomarker tests be
aware, cite and, more importantly, adhere to the criteria
put forward by the NCI Workshop Committee.
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